Jesper M. Magnusson
Rank 86 by 10-year citations to CLAD papers (28 papers, 380 citations). "Consultant" (Sahlgrenska Sjukhuset Transplantationscentrum); field: respiratory medicine.
As of . Primary source: ORCID record (role and affiliation entries are self-asserted).
Summary
Jesper M. Magnusson. Role: ORCID lists "Consultant" (Sahlgrenska Sjukhuset Transplantationscentrum). Basis of the role: ORCID employment entries without an end date (self-asserted by the record holder, may be out of date). Field indicated by the unit name: respiratory medicine (source: affiliation lines on the author's own papers, for example https://doi.org/10.1183/13993003.02351-2025 (2026): "Department of Respiratory Medicine, Institute of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden"; also on https://doi.org/10.3389/ti.2026.16295, https://doi.org/10.1016/j.healun.2026.04.). Affiliation: Sahlgrenska Sjukhuset Transplantationscentrum, Goteborg (SE). Basis: ORCID record, employment entries without an end date (self-asserted, may be out of date). Counts in the OpenAlex corpus (retrieved 2026-10-10): 28 papers and 380 citations over ten years; 6 first-author and 8 last-author papers. Ranks: main 86, excluding consensus papers 74, first or last author 63. The method is stated once on the People list page. Linked papers are the most-cited corpus papers of this author.
Citation ranks (10 years)
| Main rank | Rank excluding consensus papers | Rank by first or last author papers |
|---|---|---|
| 86 of 800 | 74 of 794 | 63 of 512 |
Citations: 380 in total, 380 excluding consensus and guideline papers (0 of this author's papers excluded), 132 on first or last author papers (6 first, 8 last).
Ranking method: see the methodology note at the top of the People list and the full methodology document.
Role and field
- Role
- "Consultant" (Sahlgrenska Sjukhuset Transplantationscentrum)
- Role status
- verified from ORCID (self-asserted entries; may be out of date)
- Role basis
- ORCID employment entries without an end date (self-asserted by the record holder, may be out of date)
- Field
- respiratory medicine
- Field basis
- affiliation lines on the author's own papers, for example https://doi.org/10.1183/13993003.02351-2025 (2026): "Department of Respiratory Medicine, Institute of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden"; also on https://doi.org/10.3389/ti.2026.16295, https://doi.org/10.1016/j.healun.2026.04.
Only what a cited source supports is stated. Entries marked self-asserted come from the person's own ORCID record. The field is taken from the name of the unit, not inferred from the person's name.
Details
- affiliation
- Sahlgrenska Sjukhuset Transplantationscentrum, Goteborg (SE)
- papers 10y
- 28
- fractional papers 10y
- 4
- citations 10y
- 380
- fractional citations 10y
- 30.7
- ranking retrieved
- 2026-10-10
- orcid
- 0000-0002-5630-0155
- openalex author id
- A5079367764
- merged open alex profiles
- 2
- affiliation basis
- ORCID record, employment entries without an end date (self-asserted, may be out of date)
- papers excluding consensus 10y
- 28
- citations excluding consensus 10y
- 380
- consensus papers excluded 10y
- 0
- first author papers 10y
- 6
- last author papers 10y
- 8
- lead author citations 10y
- 132
- lead author papers 10y
- 14
Sources and links
- ORCID record (role and affiliation entries are self-asserted) (primary)
- OpenAlex author profile (ranking source)
- Most-cited CLAD paper in corpus: Effect of once-per-day tacrolimus versus twice-per-day ciclosporin on 3-year incidence of chronic lung allograft dysfunction after lung transplantation in Scandinavia (ScanCLAD): a multicentre randomised controlled trial (The Lancet Respiratory Medicine, 2024); 47 citations; DOI 10.1016/s2213-2600(23)00293-x
- Most-cited CLAD paper in corpus: Chronic lung allograft dysfunction after lung transplantation: prevention, diagnosis and treatment in 44 European centres (ERJ Open Research, 2025); 18 citations; DOI 10.1183/23120541.00675-2024
- Most-cited CLAD paper in corpus: A European Multi‐Center, Randomized, Double‐Blind Trial of Pirfenidone in Bronchiolitis‐Obliterans‐Syndrome Grade 1‐3 in Lung Transplant Recipients (European Trial of Pirfenidone in BOS (EPOS)) (The Journal of Heart and Lung Transplantation, 2020); 13 citations; DOI 10.1016/j.healun.2020.01.1130
- Most-cited CLAD paper in corpus: Design and Rationale of a Scandinavian Multicenter Randomized Study Evaluating if Once-Daily Tacrolimus Versus Twice-Daily Cyclosporine Reduces the 3-year Incidence of Chronic Lung Allograft Dysfunction After Lung Transplantation (ScanCLAD Study) (Advances in Therapy, 2020); 9 citations; DOI 10.1007/s12325-020-01224-1
- Most-cited CLAD paper in corpus: A European multicentre, randomised controlled trial of pirfenidone in bronchiolitis obliterans syndrome after bilateral lung transplantation (European Respiratory Journal, 2026); 9 citations; DOI 10.1183/13993003.02154-2024
- ORCID employment entries (source of the role)
- Own paper naming the unit (affiliation line)
- Own paper naming the unit (affiliation line)
Related
Links from this record
Known gaps in this record
- centre membership relation (not asserted)
- funding and conflicts of interest
- only the top-30 entries were checked by hand for ID merges and splits
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.